

Case ID	Model ID	Event Index	Regimen	Status	Duration (Months)	Reason Stopped	Clinical Response	Relation to PDX Collection	Comments
WUR-016	RESL3	1	SUNITINIB MALATE	Ongoing	-	-	Non-evaluable	After	
WUR-016	RESL3	2	Axitinib	Ended	2.63	Adverse events/side effects	Non-evaluable	After	
WUR-016	RESL3	3	Pazopanib hydrochloride	Ongoing	-	-	Non-evaluable	After	
WUR-065	RESL4	1	Lenvatinib, Everolimus	Ended	12.68	Adverse events/side effects	Non-evaluable	Concurrent	
WUR-065	RESL4	2	Ipilimumab, Nivolumab	Ended	0.26	Adverse events/side effects	Off study	After	Off this treatment due to patient preference.
WUR-065	RESL4	3	Lenvatinib, Everolimus	Ongoing	-	-	Non-evaluable	After	
WUR-014	RESL5	1	Ipilimumab, Nivolumab	Ended	8.97	Disease progression	Non-evaluable	After	
WUR-014	RESL5	2	-	Ongoing	-	-	Not applicable	After	
WUR-012	RESL10	1	Axitinib, Avelumab	Ended	10.35	Disease progression	Non-evaluable	Before	
WUR-012	RESL10	2	Cabozantinib	Ended	2.5	Disease progression	Non-evaluable	Before	
WUR-012	RESL10	3	Radiation	Ended	0.23	Completed therapy	Non-evaluable	Before	
WUR-012	RESL10	4	Gemcitabine	Ended	0.72	Death on study	Non-evaluable	After	
WUR-106	RESL11	1	Pazopanib hydrochloride	Ended	1.05	Death on study	Non-evaluable	After	
WUR-154	RESL12	1	Ipilimumab, Nivolumab	Ended	2.01	Completed therapy	Non-evaluable	After	